RUNX1 and acute myeloid leukemia: There is also interest in BET protein antagonists as they restore normal hematopoiesis, cell growth and apoptosis of RUNX1-mutated leukemic blast cells, leading to improved survival in xenograft models of AML with mutant RUNX1 [73].